Alnylam Pharmaceuticals, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ALNY Nasdaq 2834 http://www.alnylam.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alnylam Pharmaceuticals, Inc.

Trade of the 2020's: Sell Gold, Buy Biotech - Dec 4th, 2019 9:53 pm
Alnylam Pharmaceuticals, Inc. (ALNY): These Hedge Funds Cashed Out Too Early - Dec 3rd, 2019 9:54 pm
Alnylam Pharmaceuticals (NASDAQ:ALNY) Is In A Strong Position To Grow Its Business - Dec 2nd, 2019 1:12 pm
The Zacks Analyst Blog Highlights: GLD, CRSP, GBT, ALNY and ARKG - Nov 29th, 2019 4:30 pm
Alnylam Gets Second Product Approval Amid Stiff Competition - Nov 29th, 2019 2:34 pm
Why Gold is Headed to Zero -- And What You Should Buy Instead - Nov 27th, 2019 10:33 pm
Alnylam Pharmaceuticals, Inc. (ALNY) Shares March Higher, Can It Continue? - Nov 26th, 2019 2:39 pm
Alnylam to Webcast Presentations at Upcoming December Investor Conferences - Nov 26th, 2019 1:00 pm
The Medicines Company to be Acquired by Novartis for $9.7B - Nov 25th, 2019 2:42 pm
Novartis Is Buying The Medicines Company for $9.7 Billion - Nov 25th, 2019 1:37 pm
Alnylam Announces 2020 Product and Pipeline Goals and Provides Updates at R&D Day - Nov 22nd, 2019 12:00 pm
Alnylam's Givosiran Gets FDA Nod for Acute Hepatic Porphyria - Nov 21st, 2019 2:54 pm
Alnylam (ALNY) Catches Eye: Stock Jumps 10.5% - Nov 21st, 2019 2:01 pm
The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon - Nov 21st, 2019 12:22 pm
Alnylam shares jump on FDA approval - Nov 20th, 2019 9:53 pm
Alnylam Announces New and Enhanced Framework for Value-Based Agreements to Accelerate Patient and Provider Access to GIVLAARI™ (givosiran) - Nov 20th, 2019 7:21 pm
Alnylam Announces Approval of GIVLAARI™ (givosiran) by the U.S. Food and Drug Administration (FDA) - Nov 20th, 2019 7:03 pm
UPDATE 2-Alnylam's rare genetic disorder drug priced at $575,000 per year - Nov 20th, 2019 6:22 pm